These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 24894652)
1. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Zhao M; Pan X; Layman R; Lustberg MB; Mrozek E; Macrae ER; Wesolowski R; Carothers S; Puhalla S; Shapiro CL; Ramaswamy B Invest New Drugs; 2014 Dec; 32(6):1285-94. PubMed ID: 24894652 [TBL] [Abstract][Full Text] [Related]
2. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311 [TBL] [Abstract][Full Text] [Related]
3. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer. Schwartzberg LS; Badarinath S; Keaton MR; Childs BH Clin Breast Cancer; 2014 Jun; 14(3):161-8. PubMed ID: 24566467 [TBL] [Abstract][Full Text] [Related]
4. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Bachelot T; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Bondarenko I; Paluch-Shimon S; Wardley A; Merot JL; du Toit Y; Easton V; Lindegger N; Miles D; Ann Oncol; 2019 May; 30(5):766-773. PubMed ID: 30796821 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149 [TBL] [Abstract][Full Text] [Related]
6. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368 [TBL] [Abstract][Full Text] [Related]
7. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866 [TBL] [Abstract][Full Text] [Related]
9. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Livingston RB; Barlow WE; Kash JJ; Albain KS; Gralow JR; Lew DL; Flaherty LE; Royce ME; Hortobagyi GN Breast Cancer Res Treat; 2011 Nov; 130(1):123-31. PubMed ID: 21826527 [TBL] [Abstract][Full Text] [Related]
10. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial. Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172 [TBL] [Abstract][Full Text] [Related]
11. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Smyth LM; Iyengar NM; Chen MF; Popper SM; Patil S; Wasserheit-Lieblich C; Argolo DF; Singh JC; Chandarlapaty S; Sugarman SM; Comen EA; Drullinsky PR; Traina TA; Troso-Sandoval T; Baselga J; Norton L; Hudis CA; Dang CT Breast Cancer Res Treat; 2016 Jul; 158(1):91-97. PubMed ID: 27306421 [TBL] [Abstract][Full Text] [Related]
12. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236 [TBL] [Abstract][Full Text] [Related]
14. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. Baselga J; Cortés J; Kim SB; Im SA; Hegg R; Im YH; Roman L; Pedrini JL; Pienkowski T; Knott A; Clark E; Benyunes MC; Ross G; Swain SM; N Engl J Med; 2012 Jan; 366(2):109-19. PubMed ID: 22149875 [TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614 [TBL] [Abstract][Full Text] [Related]
16. A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. Tryfonidis K; Boukovinas I; Xenidis N; Christophyllakis C; Papakotoulas P; Politaki E; Malamos N; Polyzos A; Kakolyris S; Georgoulias V; Mavroudis D; Breast; 2013 Dec; 22(6):1171-7. PubMed ID: 24091128 [TBL] [Abstract][Full Text] [Related]
17. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Falchook GS; Moulder SL; Wheler JJ; Jiang Y; Bastida CC; Kurzrock R Ann Oncol; 2013 Dec; 24(12):3004-11. PubMed ID: 24158411 [TBL] [Abstract][Full Text] [Related]
18. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564 [TBL] [Abstract][Full Text] [Related]
19. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer. Xie BJ; Zhu LN; Ma C; Li JB; Dong L; Zhu ZN; Ding T; Gu XS Breast Cancer; 2020 Mar; 27(2):186-196. PubMed ID: 31529262 [TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-containing regimens for metastatic breast cancer. Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]